Krebs Biochemicals & Industries Ltd
KREBSBIO NSE
Krebs Biochemicals & Industries Ltd
HealthcareNSE: KREBSBIO BSE: 524518 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹120 Cr
Volatility
Moderate
P/E Ratio
-8.5
EBITDA
₹-5.45 Cr
Return on Equity
18.42%
Debt to Equity
0
Book Value
₹-75.49
52W High
₹82.49
52W Low
₹38.33
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Krebs Biochemicals & Industries Ltd insights
29 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -15.1% over past five years.
Growth Rate
Revenue Growth
-46.07% ↘
Net Income Growth
-37.06% ↘
Cash Flow Change
-434.32% ↘
ROE
11.30% ↗
ROCE
148.03% ↗
EBITDA Margin (Avg.)
-34.95% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.1 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 |
| Expenses | 13.2 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 |
| Operating Profit | -2.62 | -0.9 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.8 | 0.3 | -0.86 | 0.82 |
| OPM % | -24.76% | -6.04% | -16.1% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% | 11.75% |
| Other Income | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0 | 2 | 0.16 |
| Interest | 1.1 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 |
| Depreciation | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.6 | 1.62 | 1.63 | 1.57 | 1.59 |
| PBT | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 | -2.49 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.24% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 | -2.48 |
| EPS in Rs | -2.47 | -1.66 | -2.31 | -2.71 | -2.4 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
Profit & Loss
| Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 | 25 |
| Expenses | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 29 | 28 |
| Operating Profit | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -5 | -3 |
| OPM % | — | -1088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -23% | -10% |
| Other Income | 3 | 1 | 0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 |
| Interest | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 | 7 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 | 6 |
| PBT | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| EPS in Rs | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.5 | -7.85 | -6.54 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 9 | 0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -184 |
| Borrowings | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 225 |
| Other Liabilities | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 101 |
| Total Liabilities | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
| Fixed Assets | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 142 |
| CWIP | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | -25 | 2 | -8 | -2 |
| Investing | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 | -4 |
| Financing | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| Net Cash Flow | 6 | -6 | 0 | 0 | 17 | -17 | 1 | -1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -48 | -23 | -17 | -9 | -1 | -45 | -40 | -41 | -36 | -5 | -11 | -5 |
| CFO/OP | 924 | 123 | 140 | 83 | -40 | 191 | 83 | 51 | 157 | -27 | 52 | 35 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | 0 |
| Inventory Days | — | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | — |
| Days Payable | — | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | — |
| Cash Conversion Cycle | — | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | 0 |
| Working Capital Days | — | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | -1,593 |
| ROCE % | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% | -15% |
Documents
1
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015.
7 May - Board meeting on May 21, 2026 to consider audited Q4 and FY2026 results. 7 May - Board meeting on May 21, 2026 to consider audited Q4 and FY2026 results.
2
Clarification On Price Movement
10 Apr - Company clarified on April 10, 2026 that no material event caused the price movement. 10 Apr - Company clarified on April 10, 2026 that no material event caused the price movement.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2026. 7 Apr - Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2026.
4
Clarification Sought from Krebs Biochemicals & Industries Ltd
8 Apr - Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure … 8 Apr - Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure …
5
Closure of Trading Window
19 Mar - Trading window closed from COB March 31, 2026 until 48 hours after audited FY2026 results; board date to be notified. 19 Mar - Trading window closed from COB March 31, 2026 until 48 hours after audited FY2026 results; board date to be notified.
Frequently Asked Questions about Krebs Biochemicals & Industries Ltd
What does Krebs Biochemicals & Industries Ltd do?
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
Where is Krebs Biochemicals & Industries Ltd (KREBSBIO) listed?
Krebs Biochemicals & Industries Ltd is listed on the Indian stock exchanges. It is listed on NSE: KREBSBIO and BSE: 524518. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Krebs Biochemicals & Industries Ltd belong to?
Krebs Biochemicals & Industries Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a market capitalisation of approximately ₹119.66 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Krebs Biochemicals & Industries Ltd?
The Price-to-Earnings (PE) ratio of Krebs Biochemicals & Industries Ltd is -8.50. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Krebs Biochemicals & Industries Ltd?
Over the past 52 weeks, Krebs Biochemicals & Industries Ltd has traded between a low of ₹38.33 and a high of ₹82.49. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a Return on Equity (ROE) of 18.42%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Krebs Biochemicals & Industries Ltd on Tapetide?
On Tapetide, you can view Krebs Biochemicals & Industries Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.